AVIR - Atea Pharmaceuticals GAAP EPS of -$0.10 beats by $0.34
- Atea Pharmaceuticals press release ( NASDAQ: AVIR ): Q3 GAAP EPS of -$0.10 beats by $0.34 .
- Cash, Cash Equivalents and Marketable Securities: $665.0 million at September 30, 2022 compared to $764.4 million at December 31, 2021.
For further details see:
Atea Pharmaceuticals GAAP EPS of -$0.10 beats by $0.34